Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2025-03-20
Target enrollment:
Participant gender:
Summary
To see the effect if a combination of neoadjuvant chemotherapy combined with Camrelizumab
followed by chemoradiotherapy in treating patients without distant metastasis nasopharyngeal
carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital